ES2167453T3 - Composicion de suministro medicamentoso que contiene quitosano o derivado del mismo con un potencial z. definido. - Google Patents

Composicion de suministro medicamentoso que contiene quitosano o derivado del mismo con un potencial z. definido.

Info

Publication number
ES2167453T3
ES2167453T3 ES95929164T ES95929164T ES2167453T3 ES 2167453 T3 ES2167453 T3 ES 2167453T3 ES 95929164 T ES95929164 T ES 95929164T ES 95929164 T ES95929164 T ES 95929164T ES 2167453 T3 ES2167453 T3 ES 2167453T3
Authority
ES
Spain
Prior art keywords
chitosane
derivative
potential
same
composition containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95929164T
Other languages
English (en)
Inventor
Peter James Watts
Lisbeth Illum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Services Ltd
Original Assignee
West Pharmaceutical Services Drug Delivery and Clinical Research Center Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by West Pharmaceutical Services Drug Delivery and Clinical Research Center Ltd filed Critical West Pharmaceutical Services Drug Delivery and Clinical Research Center Ltd
Application granted granted Critical
Publication of ES2167453T3 publication Critical patent/ES2167453T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE FACILITA UNA COMPOSICION DE SUMINISTRO MEDICAMENTOSO PARA LA ADMINISTRACION EN LA MUCOSA. LA COMPOSICION INCLUYE UN COMPUESTO Y PARTICULAS ACTIVAS FARMACOLOGICAMENTE, PREFERIBLEMENTE EN POLVO O MICROESFERAS, DE QUITOSANO O DERIVADO DE QUITOSANO O SAL EN LA QUE LAS PARTICULAS SE HALLAN BIEN SOLIDIFICADAS O PARCIALMENTE ENLAZADAS DE FORMA CRUZADA DE FORMA QUE TIENEN UN POTENCIAL-ZETA DE +0.5 A +50MV. LAS PARTICULAS SOLIDIFICADAS SE HACEN MEDIANTE EL TRATAMIENTO DE LAS PARTICULAS MEDIANTE UNA SAL DE QUITOSANO SOLUBLE EN AGUA CON UN AGENTE ALCALINO COMO EL HIDROXIDO DE SODIO EN AGUA QUE NO CONTIENE ACIDO PARA HACERLAS INSOLUBLES.
ES95929164T 1994-08-20 1995-08-21 Composicion de suministro medicamentoso que contiene quitosano o derivado del mismo con un potencial z. definido. Expired - Lifetime ES2167453T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9416884A GB9416884D0 (en) 1994-08-20 1994-08-20 Drug delivery compositions

Publications (1)

Publication Number Publication Date
ES2167453T3 true ES2167453T3 (es) 2002-05-16

Family

ID=10760170

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95929164T Expired - Lifetime ES2167453T3 (es) 1994-08-20 1995-08-21 Composicion de suministro medicamentoso que contiene quitosano o derivado del mismo con un potencial z. definido.

Country Status (13)

Country Link
US (1) US5840341A (es)
EP (1) EP0776195B1 (es)
JP (1) JPH10508004A (es)
AT (1) ATE208193T1 (es)
AU (1) AU688566B2 (es)
DE (1) DE69523765T2 (es)
DK (1) DK0776195T3 (es)
ES (1) ES2167453T3 (es)
FI (1) FI970694A7 (es)
GB (2) GB9416884D0 (es)
NO (1) NO315636B1 (es)
PT (1) PT776195E (es)
WO (1) WO1996005810A1 (es)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
GB2330532A (en) * 1996-07-10 1999-04-28 Danbiosyst Uk Compositions suitable for delivery of genes to epithelial cells
US6649192B2 (en) * 1996-07-29 2003-11-18 Universidade De Santiago De Compostela Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms
ES2114502B1 (es) * 1996-07-29 1999-07-01 Univ Santiago Compostela Aplicacion de nanoparticulas a base de polimeros hidrofilicos como formas farmaceuticas.
GB9700624D0 (en) 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
DE19712978A1 (de) * 1997-03-27 1998-10-01 Henkel Kgaa Chitosanmikrosphären
CA2302569A1 (en) * 1997-09-05 1999-03-18 Maruho Kabushikikaisha Nanocapsule preparation for treatment of intra-articular diseases
DE19756314C2 (de) * 1997-12-12 2000-06-29 Roland Bodmeier Zubereitung mit verlängerter Verweildauer am Applikationsort
JPH11246392A (ja) * 1998-03-03 1999-09-14 Makoto Otsuka 経口用固形製剤
KR100306221B1 (ko) * 1998-12-17 2002-03-21 김충섭 서방성키토산미세캡슐의제조방법
GB9905136D0 (en) 1999-03-06 1999-04-28 Danbiosyst Uk Surface modification of lamellar particles
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
EP2280004B1 (en) 1999-06-29 2016-04-20 MannKind Corporation Pharmaceutical formulations comprising insulin complexed with a diketopiperazine
EP1216043B1 (de) * 1999-10-01 2003-05-07 Degussa AG Alpha-liponsäure(-derivate)enthaltende retardform
GB9924797D0 (en) * 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
US20030206958A1 (en) * 2000-12-22 2003-11-06 Cattaneo Maurizio V. Chitosan biopolymer for the topical delivery of active agents
AU6627201A (en) * 2000-05-03 2001-11-12 Mbt Munich Biotechnology Gmbh Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
GB2378383A (en) * 2001-06-06 2003-02-12 Gursharan Moonga Nasal delivery of pharmaceutical compositions in powder form
US20030134810A1 (en) * 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
US20030224000A1 (en) * 2001-12-21 2003-12-04 Kokai-Kun John Fitzgerald Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
AU2003207508A1 (en) * 2002-01-10 2003-07-30 Northeastern University Hybrid immobilized catalytic system with controlled permeability
EP1494732B1 (en) 2002-03-20 2008-01-30 MannKind Corporation Inhalation apparatus
WO2004022579A2 (en) * 2002-09-06 2004-03-18 University Of South Florida Cellular delivery of natriuretic peptides
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
AU2003268531A1 (en) 2002-09-06 2004-03-29 University Of South Florida Materials and methods for treatment of allergic diseases
GB0302738D0 (en) * 2003-02-06 2003-03-12 Advanced Biopolymers As Composition
AU2004235744A1 (en) * 2003-05-01 2004-11-18 Archimedes Development Limited Nasal administration of the LH-RH analog leuprolide
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
US20050147581A1 (en) * 2003-11-19 2005-07-07 The Board Of Trustees Of The University Of Illinois Macromolecular drug complexes having improved stability and therapeutic use of the same
US20050175679A1 (en) * 2004-02-10 2005-08-11 Michael Moshman Controlled release formulations
WO2005094420A2 (en) * 2004-02-17 2005-10-13 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
EP1742612A2 (en) * 2004-05-06 2007-01-17 Ivrea Pharmaceuticals, Inc. Particles for the delivery of active agents
DK1786784T3 (da) 2004-08-20 2011-02-14 Mannkind Corp Katalyse af diketopiperazinsyntese
CN104436170B (zh) 2004-08-23 2018-02-23 曼金德公司 用于药物输送的二酮哌嗪盐
US7892414B1 (en) 2004-11-19 2011-02-22 The United States Of America As Represented By The Secretary Of Army Electrochemical biosensors, applications and methods of making biosensors
ES2277743B2 (es) * 2005-06-02 2008-12-16 Universidade De Santiago De Compostela Nanoparticulas que comprenden quitosano y ciclodextrina.
AU2006290227B2 (en) 2005-09-14 2012-08-02 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
KR20080096809A (ko) 2006-02-22 2008-11-03 맨카인드 코포레이션 디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법
AU2007285472B2 (en) * 2006-03-30 2013-10-24 Engene, Inc. Non-viral compositions and methods for transfecting gut cells in vivo
CA2656990A1 (en) * 2006-04-28 2007-11-08 University Of South Florida Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
PT2028937E (pt) * 2006-05-22 2015-04-09 Vanda Pharmaceuticals Inc Tratamento por agonista de melatonina
CN101148511B (zh) * 2006-09-18 2010-10-20 中国科学院过程工程研究所 荧光壳聚糖微球的制备方法及其在示踪剂领域的应用
WO2008091588A1 (en) 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
CN104874007A (zh) 2007-08-28 2015-09-02 奥塔哥创新有限公司 手术用水凝胶
GB0716907D0 (en) 2007-08-31 2007-10-10 Archimedes Dev Ltd Pharmaceutical powder compositions
EP2057982A1 (en) 2007-11-09 2009-05-13 Archimedes Development Limited Intranasal compositions
US9198997B2 (en) 2008-04-24 2015-12-01 Medtronic, Inc. Rehydratable thiolated polysaccharide particles and sponge
EP2288389B1 (en) 2008-04-24 2014-06-11 Medtronic, Inc Cold ionizing radiation sterilization
EP2310002B1 (en) * 2008-04-24 2016-11-02 Medtronic, Inc Protective gel based on chitosan and oxidized polysaccharide
EP2296637B1 (en) 2008-04-24 2014-04-02 Medtronic, Inc Chitosan-containing protective composition
EP2123261A1 (en) * 2008-05-20 2009-11-25 Stallergenes S.A. Mucoadhesive particulate formulation for inducing antigen-specific immune tolerance
SG10201507036TA (en) 2008-06-13 2015-10-29 Mannkind Corp A dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
EP2609954B1 (en) 2008-06-20 2021-12-29 MannKind Corporation An interactive apparatus for real-time profiling of inhalation efforts
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
JP2009149675A (ja) * 2009-02-24 2009-07-09 Novadel Pharma Inc 極性または非極性の、バッカルスプレーまたはカプセル
MX2011009512A (es) 2009-03-11 2011-11-29 Mannkind Corp Aparato, sistema y metodo para medir la resistencia de un inhalador.
MY157166A (en) 2009-06-12 2016-05-13 Mankind Corp Diketopiperazine microparticles with defined specific surface areas
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
IL223742A (en) 2010-06-21 2016-06-30 Mannkind Corp A dry powder inhaler and preparation for it
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
EP2694402B1 (en) 2011-04-01 2017-03-22 MannKind Corporation Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
HK1200318A1 (en) 2011-10-24 2015-08-07 曼金德公司 Methods and compositions for treating pain
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
CA3085116C (en) 2012-01-26 2022-07-19 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
EP2872205B1 (en) 2012-07-12 2017-02-08 MannKind Corporation Dry powder drug delivery systems
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
KR102148990B1 (ko) 2012-12-18 2020-08-27 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
WO2014144895A1 (en) 2013-03-15 2014-09-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
PL2978482T3 (pl) * 2013-03-26 2022-10-03 Optinose As Podawanie donosowe
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
KR102465025B1 (ko) 2013-07-18 2022-11-09 맨카인드 코포레이션 열-안정성 건조 분말 약제학적 조성물 및 방법
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
JP6945614B2 (ja) * 2014-03-26 2021-10-06 オプティノーズ アズ 経鼻投与
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
MX390453B (es) * 2014-06-25 2025-03-19 Optinose Inc Administracion nasal.
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
JOP20180128A1 (ar) * 2018-12-24 2020-06-24 Univ Of Petra صيغة دوائية صلبة قابلة للتشتت في الفم

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4895724A (en) * 1985-06-07 1990-01-23 Pfizer Inc. Chitosan compositions for controlled and prolonged release of macromolecules
US5129877A (en) * 1988-04-29 1992-07-14 University Of Georgia Research Foundation, Inc. Receptor-mediated delivery system
GB8904370D0 (en) * 1989-02-25 1989-04-12 Cosmas Damian Ltd Liquid delivery compositions
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration

Also Published As

Publication number Publication date
GB9702503D0 (en) 1997-03-26
GB2305124A (en) 1997-04-02
GB9416884D0 (en) 1994-10-12
DE69523765D1 (de) 2001-12-13
FI970694A0 (fi) 1997-02-19
ATE208193T1 (de) 2001-11-15
NO970507D0 (no) 1997-02-05
JPH10508004A (ja) 1998-08-04
DE69523765T2 (de) 2002-09-26
EP0776195B1 (en) 2001-11-07
AU3262695A (en) 1996-03-14
NO970507L (no) 1997-02-05
DK0776195T3 (da) 2001-12-27
AU688566B2 (en) 1998-03-12
PT776195E (pt) 2002-04-29
US5840341A (en) 1998-11-24
FI970694L (fi) 1997-02-19
WO1996005810A1 (en) 1996-02-29
NO315636B1 (no) 2003-10-06
FI970694A7 (fi) 1997-02-19
EP0776195A1 (en) 1997-06-04
GB2305124B (en) 1998-11-18

Similar Documents

Publication Publication Date Title
GB2305124A (en) Drug delivery composition containing chitosan or derivative thereof having a defined z.potential
ES2094539T3 (es) Preparacion farmaceutica y procedimiento para su preparacion.
UA26455C2 (uk) Лікарський препарат у формі таблеток із сповільhеhим вивільhеhhям активhого іhгредієhта
SI1553927T1 (sl) Z gelom stabilizirani nanodeläśni sestavki uäśinkovine
ES2137350T3 (es) Formulacion farmaceutica.
FI943315A0 (fi) Farmaseuttinen valmiste pore- ja/tai hajoamistabletin tai pikarakeiden muodossa, samoin kuin menetelmä valmistaa niitä
BR9710115A (pt) Processo para aplicar partìculas sólidas de um medicamento em superfìcies de mucosa das cavidade nasais, composição aquosa farmacêutica, e , processo de preparação de uma composição aquosa farmacêutica.
HUT70416A (en) Insoluble preparation with immediate release core and instained release coating
IL120317A0 (en) Otic antibacterial compositions
AR027391A1 (es) Composiciones farmaceuticas de toxina botulinica
IL133614A0 (en) Medicinal compositions for application to mucosa
ID28510A (id) Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
PE33396A1 (es) Composicion para el tratamiento del ansia de nicotina y/o los sintomas de abstinencia de fumar
CO4970795A1 (es) Polisacaridos de sintesis, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
CO5261494A1 (es) Composiciones farmaceuticas acuosas e hipotonicas de ciclesonida que presentan absorcion nasal mejorada
PE22995A1 (es) Composicion de tiotepa liofilizada estable
HUP9902415A2 (hu) Azonnal felszabaduló szilárd beadási formák és eljárás azok előállítására
CO4960657A1 (es) Composicion farmaceutica
GR3018337T3 (en) Topical application composition.
AR040279A2 (es) Composiciones que contiene sal de sertralina
ES2067052T3 (es) Procedimiento para el tratamiento final de tensioactivos anfoteros o zwitterionicos.
ES2092559T3 (es) Formulacion farmaceutica que contiene penciclovir.
CO5640085A2 (es) Formulaciones farmaceuticas que comprenden amoxicilina y clavulanato
ES2186415T3 (es) Composiciones detergentes y para ablandar el agua.
AR044697A1 (es) Formulaciones farmaceuticas que comprenden amoxicilina y clavulanato